Glucagon-like peptide-1 receptor (GLP-1) agonists, widely used to treat obesity and diabetes, may also improve key outcomes for patients with Crohns disease, according to a large real-world study presented during the 2026 Crohns & Colitis Congress, a partnership of AGA and the Crohn's & Colitis Foundation, taking place in Las Vegas
Unlike synthetic interventions, activating L-cells through diet and lifestyle works with your innate physiology to support healthy metabolic function
Hatzivassiliou G, Zhao F, Bauer DE, Andreadis C, Shaw AN, Dhanak D, Hingorani SR, Tuveson DA, Thompson CB
This material is intended for analytical and controlled research applications
Many people report feeling full faster during meals and experiencing fewer cravings between meals
Ozempic is available in injectable form